

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



RemeGen Co., Ltd.*

榮昌生物製藥(煙台)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 9995)

DISCLOSABLE TRANSACTION PURCHASE OF WEALTH MANAGEMENT PRODUCTS

PURCHASE OF WEALTH MANAGEMENT PRODUCTS

At the 36th meeting held by the second session of the Board on March 27, 2026, (1) a resolution regarding cash management using self-owned funds was considered and approved, pursuant to which the Company may purchase wealth management products using part of idle self-owned funds of not more than RMB2,500.0 million; and (2) a resolution regarding cash management using idle raised proceeds was considered and approved, pursuant to which the Company may purchase principal-guaranteed wealth management products using part of idle raised proceeds from A shares of not more than RMB80.0 million.

As disclosed in the announcements of the Company dated May 13, 2026 and July 2, 2026, (1) on May 6, 2026, the Company entered into the SPDB Wealth Management Product Agreement No. 5 with SPDB Yantai Branch, pursuant to which the Company agreed to purchase wealth management product of an amount of RMB200.0 million from SPDB Yantai Branch using idle self-owned funds; (2) on May 13, 2026, the Company entered into the SPDB Wealth Management Product Agreement No. 7 with SPDB Yantai Branch, pursuant to which the Company agreed to purchase wealth management product of an amount of RMB100.0 million from SPDB Yantai Branch using idle self-owned funds; and (3) on July 2, 2026, the Company entered into the SPDB Wealth Management Product Agreement No. 9 with SPDB Yantai Branch, pursuant to which the Company agreed to purchase wealth management product of an amount of RMB80.0 million from SPDB Yantai Branch using idle raised proceeds.

The Board announces that, on September 2, 2026, the Company further entered into the SPDB Wealth Management Product Agreement No. 11 with SPDB Yantai Branch, pursuant to which the Company agreed to purchase wealth management product of an amount of RMB300.0 million from SPDB Yantai Branch using idle self-owned funds.

LISTING RULES IMPLICATIONS

As the Company entered into (1) the SPDB Wealth Management Product Agreement No. 5 with SPDB Yantai Branch on May 6, 2026, (2) the SPDB Wealth Management Product Agreement No. 7 with SPDB Yantai Branch on May 13, 2026, and (3) the SPDB Wealth Management Product Agreement No. 9 with SPDB Yantai Branch on July 2, 2026, and still holds the wealth management products under such agreements, and the transactions contemplated under (1) the SPDB Wealth Management Product Agreement No. 5, (2) the SPDB Wealth Management Product Agreement No. 7, (3) the SPDB Wealth Management Product Agreement No. 9 and (4) the SPDB Wealth Management Product Agreement No. 11 are conducted with the same bank and are of similar nature within a 12-month period, for the purpose of calculating the relevant percentage ratios under Rule 14.22 of the Listing Rules, these transactions shall be aggregated in each case as if they were one transaction with the said bank.

As one of the applicable percentage ratios (as defined under Rule 14.07 of the Listing Rules) in respect of the SPDB Wealth Management Product Agreements exceeds 5% but all of the applicable percentage ratios are less than 25%, the purchase of wealth management products under the SPDB Wealth Management Product Agreements therefore constitutes a discloseable transaction of the Company under Chapter 14 of the Listing Rules and is subject to the reporting and announcement requirements under the Listing Rules.

BACKGROUND

On May 6, 2026, the Company entered into the SPDB Wealth Management Product Agreement No. 5 with SPDB Yantai Branch, pursuant to which the Company agreed to purchase wealth management product of an amount of RMB200.0 million from SPDB Yantai Branch using idle self-owned funds.

On May 13, 2026, the Company entered into the SPDB Wealth Management Product Agreement No. 7 with SPDB Yantai Branch, pursuant to which the Company agreed to purchase wealth management product of an amount of RMB100.0 million from SPDB Yantai Branch using idle self-owned funds.

On July 2, 2026, the Company entered into the SPDB Wealth Management Product Agreement No. 9 with SPDB Yantai Branch, pursuant to which the Company agreed to purchase wealth management product of an amount of RMB80.0 million from SPDB Yantai Branch using idle raised proceeds.

The Board announces that, on September 2, 2026, the Company further entered into the SPDB Wealth Management Product Agreement No. 11 with SPDB Yantai Branch, pursuant to which the Company agreed to purchase wealth management product of an amount of RMB300.0 million from SPDB Yantai Branch using idle self-owned funds.

SPDB WEALTH MANAGEMENT PRODUCT AGREEMENT NO. 11

The principal terms of the SPDB Wealth Management Product Agreement No. 11 are set out as follows:

Name of product	:	Liduoduo Corporate Stable Profit 99JG3242 (Three-Tier Bullish) RMB Corporate Structured Deposit (利多多公司穩利 99JG3242 期(三層看漲)人民幣對公結構性存款)
Type of product	:	Principal-guaranteed with floating income
Linked target	:	EUR-USD exchange rate
Principal amount	:	RMB300.0 million
Validity period of product	:	36 days
Effective date of product	:	September 2, 2026
Expiry date of product	:	October 8, 2026
Expected annualized yield rate	:	0.7% or 1.75% or 1.95%
Right of early termination	:	SPDB Yantai Branch has the right to early terminate the agreement.
Investment scope	:	The proceeds from the sales of this structured deposit product will be nominal principal, the capital costs of which will be used to enter into transactions with counterparty to make investment in financial derivatives linked to the counterparty's investment income and the EUR-USD spot rate.

The terms of the SPDB Wealth Management Product Agreement No.11 were determined upon arm's length negotiations between the parties.

INFORMATION ON THE PARTIES

The Company is a commercial-ready biopharmaceutical company committed to the discovery, development and commercialization of innovative and differentiated biologics for the treatment of autoimmune, oncology and ophthalmic diseases with unmet medical needs in China and globally.

SPDB is a bank incorporated in the PRC, the shares of which are listed on the Shanghai Stock Exchange (stock code: 600000). The principal businesses of SPDB are providing corporate and personal banking services, conducting treasury business, and providing asset management and other financial services. SPDB Yantai Branch is a branch of SPDB.

To the best knowledge, information and belief of the Directors having made all reasonable enquiries, SPDB Yantai Branch, SPDB and their ultimate substantial beneficial owners as publicly disclosed by SPDB are third parties independent from the Company and its connected persons.

REASONS AND BENEFITS FOR ENTERING INTO THE SPDB WEALTH MANAGEMENT PRODUCT AGREEMENT NO.11

On the premise of strictly controlling investment risks, the Company intends to fully revitalize idle self-owned funds and improve capital utilization efficiency by deploying and managing idle funds through bank wealth management products. The allocated low-to-medium risk products feature overall controllable risks and yields higher than those of bank time deposits for the same period, which can effectively boost the investment returns on idle funds.

The Directors consider that the terms of the SPDB Wealth Management Product Agreement No.11 and the transactions contemplated thereunder are fair and reasonable, on normal commercial terms or better in the ordinary course of business of the Group, and are in the interests of the Company and its Shareholders as a whole.

LISTING RULES IMPLICATIONS

As the Company entered into (1) the SPDB Wealth Management Product Agreement No. 5 with SPDB Yantai Branch on May 6, 2026, (2) the SPDB Wealth Management Product Agreement No. 7 with SPDB Yantai Branch on May 13, 2026, and (3) the SPDB Wealth Management Product Agreement No. 9 with SPDB Yantai Branch on July 2, 2026, and still holds the wealth management products under such agreements, and the transactions contemplated under (1) the SPDB Wealth Management Product Agreement No. 5, (2) the SPDB Wealth Management Product Agreement No. 7, (3) the SPDB Wealth Management Product Agreement No. 9 and (4) the SPDB Wealth Management Product Agreement No. 11 are conducted with the same bank and are of similar nature within a 12-month period, for the purpose of calculating the relevant percentage ratios under Rule 14.22 of the Listing Rules, these transactions shall be aggregated in each case as if they were one transaction with the said bank.

As one of the applicable percentage ratios (as defined under Rule 14.07 of the Listing Rules) in respect of the SPDB Wealth Management Product Agreements exceeds 5% but all of the applicable percentage ratios are less than 25%, the purchase of wealth management products under the SPDB Wealth Management Product Agreements therefore constitutes a discloseable transaction of the Company under Chapter 14 of the Listing Rules and is subject to the reporting and announcement requirements under the Listing Rules.

DEFINITIONS

Unless the context otherwise requires, the following terms used herein have the following meanings:

“Board”	the board of Directors
“Company”	RemeGen Co., Ltd.* (榮昌生物製藥(煙台)股份有限公司), a joint stock company incorporated in the PRC with limited liability, the H shares and A shares of which are listed on the Main Board of the Stock Exchange (stock code: 9995) and the Science and Technology Innovation Board of the Shanghai Stock Exchange (stock code: 688331), respectively
“connected person”	has the meaning ascribed to it under the Listing Rules
“Director(s)”	the director(s) of the Company
“EUR”	Euro, the lawful currency of the European Union
“Group”	the Company and its subsidiaries
“Hong Kong”	the Hong Kong Special Administrative Region of the People’s Republic of China
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange
“PRC” or “China”	the People’s Republic of China excluding, for the purpose of this announcement, Hong Kong, the Macau Special Administrative Region of the People’s Republic of China and Taiwan
“RMB”	Renminbi, the lawful currency of the PRC
“Shareholder(s)”	holder(s) of the shares of the Company
“SPDB”	Shanghai Pudong Development Bank Co., Ltd., a bank incorporated in the PRC
“SPDB Wealth Management Product Agreements”	SPDB Wealth Management Product Agreement No. 5, SPDB Wealth Management Product Agreement No. 7, SPDB Wealth Management Product Agreement No. 9, and SPDB Wealth Management Product Agreement No. 11
“SPDB Wealth Management Product Agreement No. 5”	the wealth management product agreement entered into between the Company and SPDB Yantai Branch dated May 6, 2026 in relation to the purchase of wealth management product in the amount of RMB200.0 million

“SPDB Wealth Management Product Agreement No. 7”	the wealth management product agreement entered into between the Company and SPDB Yantai Branch dated May 13, 2026 in relation to the purchase of wealth management product in the amount of RMB100.0 million
“SPDB Wealth Management Product Agreement No. 9”	the wealth management product agreement entered into between the Company and SPDB Yantai Branch dated July 2, 2026 in relation to the purchase of wealth management product in the amount of RMB80.0 million
“SPDB Wealth Management Product Agreement No. 11”	the wealth management product agreement entered into between the Company and SPDB Yantai Branch dated September 2, 2026 in relation to the purchase of wealth management product in the amount of RMB300.0 million
“SPDB Yantai Branch”	Yantai Branch of Shanghai Pudong Development Bank Co., Ltd.
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“USD”	United States dollar, the lawful currency of the United States of America
“%”	percent

By order of the Board
RemeGen Co., Ltd.*
Mr. Wang Weidong
Chairman and Executive Director

Yantai, the PRC
September 2, 2026

As at the date of this announcement, the Board comprises Mr. Wang Weidong, Dr. Fang Jianmin, Mr. Wen Qingkai, Ms. Fang Michelle Yi and Mr. Wang Yuxiao as the executive Directors, Dr. Wang Liqiang as the non-executive Director, and Mr. Song Xiliang, Mr. Huang Guobin and Mr. Chen Yunjin as the independent non-executive Directors.

* For identification purpose only